GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    Cambridge University Press (CUP) ; 2023
    In:  Cambridge Prisms: Precision Medicine Vol. 1 ( 2023)
    In: Cambridge Prisms: Precision Medicine, Cambridge University Press (CUP), Vol. 1 ( 2023)
    Abstract: Drug development is essential to the advancement of human health, however, the process is slow, costly, and at high risk of failure at all stages. A promising strategy for expediting and improving the probability of success in the drug development process is the use of naturally randomized human genetic variation for drug target identification and validation. These data can be harnessed using the Mendelian randomization (MR) analytic paradigm to proxy the lifelong consequences of genetic perturbations of drug targets. In this review, we discuss the myriad applications of the MR paradigm for human drug target identification and validation. We review the methodology and applications of MR, key limitations of MR, and potential future opportunities for research. Throughout the review, we refer to illustrative examples of MR analyses investigating the consequences of genetic inhibition of interleukin 6 signaling which, in some cases, have anticipated results from randomized controlled trials. As human genetic data become more widely available, we predict that MR will serve as a key pillar of support for drug development efforts.
    Type of Medium: Online Resource
    ISSN: 2752-6143
    Language: English
    Publisher: Cambridge University Press (CUP)
    Publication Date: 2023
    detail.hit.zdb_id: 3158049-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    Online Resource
    Online Resource
    Oxford University Press (OUP) ; 2019
    In:  Sleep Vol. 42, No. Supplement_1 ( 2019-04-13), p. A263-A264
    In: Sleep, Oxford University Press (OUP), Vol. 42, No. Supplement_1 ( 2019-04-13), p. A263-A264
    Type of Medium: Online Resource
    ISSN: 0161-8105 , 1550-9109
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2019
    detail.hit.zdb_id: 2056761-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    Online Resource
    Online Resource
    Oxford University Press (OUP) ; 2019
    In:  Sleep Vol. 42, No. Supplement_1 ( 2019-04-13), p. A336-A337
    In: Sleep, Oxford University Press (OUP), Vol. 42, No. Supplement_1 ( 2019-04-13), p. A336-A337
    Type of Medium: Online Resource
    ISSN: 0161-8105 , 1550-9109
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2019
    detail.hit.zdb_id: 2056761-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    Online Resource
    Online Resource
    American Medical Association (AMA) ; 2021
    In:  JAMA Psychiatry Vol. 78, No. 8 ( 2021-08-01), p. 903-
    In: JAMA Psychiatry, American Medical Association (AMA), Vol. 78, No. 8 ( 2021-08-01), p. 903-
    Type of Medium: Online Resource
    ISSN: 2168-622X
    Language: English
    Publisher: American Medical Association (AMA)
    Publication Date: 2021
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    Online Resource
    Online Resource
    Elsevier BV ; 2019
    In:  Journal of the American College of Cardiology Vol. 74, No. 10 ( 2019-09), p. 1304-1314
    In: Journal of the American College of Cardiology, Elsevier BV, Vol. 74, No. 10 ( 2019-09), p. 1304-1314
    Type of Medium: Online Resource
    ISSN: 0735-1097
    RVK:
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2019
    detail.hit.zdb_id: 1468327-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    Online Resource
    Online Resource
    Elsevier BV ; 2021
    In:  Clinical Nutrition Vol. 40, No. 4 ( 2021-04), p. 2456-2459
    In: Clinical Nutrition, Elsevier BV, Vol. 40, No. 4 ( 2021-04), p. 2456-2459
    Type of Medium: Online Resource
    ISSN: 0261-5614
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2021
    detail.hit.zdb_id: 2009052-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    In: Neuropsychopharmacology, Springer Science and Business Media LLC, Vol. 47, No. 9 ( 2022-08), p. 1672-1679
    Abstract: Insomnia and restless leg syndrome (RLS) are associated with increased risk for suicidal behavior (SB), which is often comorbid with mood or thought disorders; however, it is unclear whether these relationships are causal. We performed a two-sample Mendelian randomization study using summary-level genetic associations with insomnia symptoms and RLS against the outcomes of risk of major depressive disorder (MDD), bipolar disorder (BP), schizophrenia (SCZ), and SB. The inverse-variance weighted method was used in the main analysis. We performed replication and sensitivity analyses to examine the robustness of the results. We identified outcome cohorts for MDD ( n  = 170,756 cases/329,443 controls), BP ( n  = 20,352/31,358), SCZ ( n  = 69,369/236,642), SB-Cohort-2019 ( n  = 6569/14,996 all with MDD, BP or SCZ; and SB within individual disease categories), and SB-Cohort-2020 ( n  = 29,782/519,961). Genetically proxied liability to insomnia symptoms significantly associated with increased risk of MDD (odds ratio (OR) = 1.23, 95% confidence interval (CI) = 1.2–1.26, P  = 1.37 × 10 –61 ), BP (OR = 1.15, 95% CI = 1.07–1.23, P  = 5.11 × 10 –5 ), SB-Cohort-2019 (OR = 1.17, 95% CI = 1.07–1.27, P  = 2.30 × 10 –4 ), SB-Cohort-2019 in depressed patients (OR = 1.34, 95% CI = 1.16–1.54, P  = 5.97 × 10 –5 ), and SB-Cohort-2020 (OR = 1.24, 95% CI = 1.18–1.3, P  = 1.47 × 10 –18 ). Genetically proxied liability to RLS did not significantly influence the risk of any of the outcomes (all corrected P   〉  0.05). Results were replicated for insomnia with MDD and SB in Mass General Brigham Biobank and were consistent in multiple lines of sensitivity analyses. In conclusion, human genetic evidence supports for the first time a potentially independent and causal effect of insomnia on SB and encourages further clinical investigation of treatment of insomnia for prevention or treatment of SB.
    Type of Medium: Online Resource
    ISSN: 0893-133X , 1740-634X
    RVK:
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2022
    detail.hit.zdb_id: 2008300-2
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    Online Resource
    Online Resource
    SAGE Publications ; 2020
    In:  Cephalalgia Vol. 40, No. 9 ( 2020-08), p. 998-1002
    In: Cephalalgia, SAGE Publications, Vol. 40, No. 9 ( 2020-08), p. 998-1002
    Abstract: To investigate potential causality between genetic liability to migraine and Alzheimer’s disease, intelligence, and brain volume using two-sample Mendelian randomization. Methods The exposure consisted of independent genetic variants associated with migraine in the largest (59,674 cases/316,078 controls) published genome-wide association study. Outcomes included Alzheimer’s disease (71,880 cases/383,378 controls), a measure of general intelligence (n = 269,867), intracranial volume (n = 11,373), and seven subcortical brain volumes (n ∼ 13,000), all with available genome-wide association study summary statistics. Mendelian randomization effects were estimated using inverse-variance weighted analysis. Results Genetic liability to migraine did not associate with Alzheimer’s disease (odds ratio [95% confidence interval] 1.01 [1.00–1.02] , p = 0.07), intelligence (standardized beta [95% confidence interval] 0.01 [0.00–0.02] , p = 0.13), or any brain volume measures (all p  〉  0.05). No individual migraine variant associated with any of the outcomes at genome-wide significance. Conclusions These data do not support a causal effect of migraine liability on Alzheimer’s disease, intelligence, or brain volume.
    Type of Medium: Online Resource
    ISSN: 0333-1024 , 1468-2982
    Language: English
    Publisher: SAGE Publications
    Publication Date: 2020
    detail.hit.zdb_id: 2019999-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    Online Resource
    Online Resource
    Wiley ; 2021
    In:  British Journal of Clinical Pharmacology Vol. 87, No. 10 ( 2021-10), p. 3916-3924
    In: British Journal of Clinical Pharmacology, Wiley, Vol. 87, No. 10 ( 2021-10), p. 3916-3924
    Abstract: It is unknown whether long‐term low‐density lipoprotein cholesterol (LDL‐c) lowering increases lifespan and longevity in a general population not selected for elevated cardiovascular risk. The present study aimed to investigate the overall and gene‐specific effect of circulating LDL‐c levels on lifespan and longevity in a general population. Methods Leveraging data from the Global Lipids Genetics Consortium ( n =  173 082), we identified genetic variants to proxy LDL‐c levels generally, and also through perturbation of particular drug targets (HMGCR, NPC1L1 and PCSK9). We investigated their association with lifespan ( n =  1 012 240) using Mendelian randomization, and replicated results using the outcome of longevity to the 90th vs . 60th percentile age (11 262 cases/25 483 controls). Results A 1‐standard deviation increase in genetically proxied LDL‐c was associated with 1.2 years lower lifespan (95% confidence interval [CI] −1.55, −0.87; P  = 3.83 × 10 −12 ). Findings were consistent in statistical sensitivity analyses, and when considering the outcome of longevity (odds ratio for survival to the 90th vs 60th percentile age 0.72, 95% CI 0.64, 0.81, P  = 7.83 × 10 −8 ). Gene‐specific Mendelian randomization analyses showed a significant effect of LDL‐c modification through PCSK9 on lifespan (−0.99 years, 95% CI −1.43, 0.55, P =  6.80 × 10 −6 ); however, estimates for HMGCR and NPC1L1 were underpowered. Conclusions This genetic evidence supports that higher LDL‐c levels reduce lifespan and longevity. In a general population that is not selected for increased cardiovascular risk, there is likely to be a net lifespan benefit of LDL‐c lowering therapies, particularly for PCSK9 inhibitors, although randomized controlled trials are necessary before modification of clinical practice.
    Type of Medium: Online Resource
    ISSN: 0306-5251 , 1365-2125
    URL: Issue
    RVK:
    Language: English
    Publisher: Wiley
    Publication Date: 2021
    detail.hit.zdb_id: 1498142-7
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    Online Resource
    Online Resource
    BMJ ; 2023
    In:  BMJ Medicine Vol. 2, No. 1 ( 2023-05), p. e000354-
    In: BMJ Medicine, BMJ, Vol. 2, No. 1 ( 2023-05), p. e000354-
    Abstract: To examine whether genetically proxied lean mass is associated with risk of Alzheimer’s disease. Design Mendelian randomisation study. Setting The UK Biobank study and genome wide association study meta-analyses of Alzheimer’s disease and cognitive performance. Participants Summary level genetic data from: 450 243 UK Biobank participants with impedance measures of lean mass and fat mass; an independent sample of 21 982 patients with Alzheimer’s disease and 41 944 controls without Alzheimer’s disease; a replication sample of 7329 patients with Alzheimer’s disease and 252 879 controls; and 269 867 individuals taking part in a genome wide association study of cognitive performance. Main outcome measure Effect of genetically proxied lean mass on the risk of Alzheimer’s disease, and the related phenotype of cognitive performance. Results An increase in genetically proxied appendicular lean mass of one standard deviation was associated with a 12% reduced risk of Alzheimer’s disease (odds ratio 0.88, 95% confidence interval 0.82 to 0.95, P=0.001). This finding was replicated in an independent cohort of patients with Alzheimer’s disease (0.91, 0.83 to 0.99, P=0.02) and was consistent in sensitivity analyses that are more robust to the inclusion of pleiotropic variants. Higher genetically proxied appendicular lean mass was also associated with increased cognitive performance (standard deviation increase in cognitive performance for each standard deviation increase in appendicular lean mass 0.09, 95% confidence interval 0.06 to 0.11, P=0.001), and adjusting for potential mediation through genetically proxied cognitive performance did not reduce the association between appendicular lean mass and risk of Alzheimer’s disease. Similar results were found for the outcomes of Alzheimer’s disease and cognitive performance when the risk factors of genetically proxied trunk lean mass and whole body lean mass were used, respectively, adjusted for genetically proxied fat mass. Conclusions These findings suggest that lean mass might be a possible modifiable protective factor for Alzheimer’s disease. The mechanisms underlying this finding, as well as the clinical and public health implications, warrant further investigation.
    Type of Medium: Online Resource
    ISSN: 2754-0413
    Language: English
    Publisher: BMJ
    Publication Date: 2023
    detail.hit.zdb_id: 3128592-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...